Showing 1571-1580 of 1746 results for "".
- AmblyoPlay Now Offers its Vision Therapy Solution for Lazy Eye in the United Stateshttps://modernod.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/AmblyoPlay, a home-based vision therapy solution for children and adults with amblyopia (lazy eye), mild strabismus (crossed or turned eye) or convergence insufficiency (eyes unable to focus together), announced the launch of its software-based vision therapy solution in the U.S. market. I
- AlpineInvestors to Make Strategic Growth Investments in Ohio Eye Care Businesseshttps://modernod.com/news/alpineinvestors-to-make-strategic-growth-investments-in-ohio-eye-care-businesses/2476694/Private equity firm Alpine Investors has invested in Ohio-based eye care business, Northeast Ohio Eye Surgeons (NEOES), including its subsidiary business, Ohio Eye Care Consultants (OECC). The two companies will together form a new ophthalmology platform for Alpine, and will continue to operate i
- Avellino Labs Founder Gene Lee Receives 2019 Ellis Island Medal of Honorhttps://modernod.com/news/avellino-labs-founder-gene-lee-receives-2019-ellis-island-medal-of-honor/2476683/Avellino Labs announced the company’s founder, chairman, and president, Gene Lee, is a recipient of a 2019 Ellis Island Medal of Honor. In addition, Mr. Lee has been appointed to the World Economic Forum’s Precision Medicine Council. One of the nation’s most prestigious awards, the Ellis I
- Alimera Sciences Appoints Samer Kaba, MD, as Chief Medical Officerhttps://modernod.com/news/alimera-sciences-appoints-samer-kaba-md-as-chief-medical-officer/2476464/Alimera Sciences announced an expansion of its leadership team with the appointment of Samer Kaba, MD, as Chief Medical Officer, effective April 4, 2019. “I am very pleased that Samer will be joining us in this new position as he will bring both a physician’s perspect
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- VSP Global Announces Executive Team Appointmentshttps://modernod.com/news/vsp-global-announces-executive-team-appointments/2479797/VSP Global announced the appointments of Earnie Franklin as chief technology officer (CTO), and Alec Mahmood as chief financial officer (CFO). Mr. Franklin and Mr. Mahmood will report to Michael Guyette, VSP Global’s president and CEO. “I am thrilled to welcome these two phenomenal l